{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:19:05Z","timestamp":1788531545814,"version":"build-2803163510"},"reference-count":247,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.colsurfb.2026.115981","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:02:50Z","timestamp":1783954970000},"page":"115981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Reprogramming hepatocellular carcinoma: Nanomedicine at the crossroads of molecular targets and smart delivery"],"prefix":"10.1016","volume":"268","author":[{"given":"Khaled","family":"Mahmoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Teaima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Nabarawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0861-2699","authenticated-orcid":false,"given":"Shady","family":"Swidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.colsurfb.2026.115981_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.colsurfb.2026.115981_bib2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jceh.2019.01.004","article-title":"Hepatocellular Carcinoma: Etiology and Current and Future Drugs","volume":"9","author":"Jindal","year":"2019","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.2010-S4-14","article-title":"The Etiology of Hepatocellular Carcinoma and Consequences for Treatment","volume":"15","author":"Sanyal","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.colsurfb.2026.115981_bib5","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.6946.1","article-title":"Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances","volume":"5","author":"Dhanasekaran","year":"2016","journal-title":"F1000Res."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115981_bib6","article-title":"Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis","volume":"16","author":"Ghouri","year":"2017","journal-title":"J. Carcinog."},{"key":"10.1016\/j.colsurfb.2026.115981_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4254\/wjh.v11.i1.1","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review","volume":"11","author":"Desai","year":"2019","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib8","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.3389\/fonc.2020.601710","article-title":"Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease","volume":"10","author":"Suresh","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2045-3701-1-5","article-title":"Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine?","volume":"1","author":"Kumar","year":"2011","journal-title":"Cell. Biosci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020491","article-title":"Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma","volume":"12","author":"Dimri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.colsurfb.2026.115981_bib11","article-title":"Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy","volume":"5","author":"Luo","year":"2024","journal-title":"MedComm (Beijing)"},{"key":"10.1016\/j.colsurfb.2026.115981_bib12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12935-021-01924-w","article-title":"Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches","volume":"21","author":"Farzaneh","year":"2021","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.colsurfb.2026.115981_bib13","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1038\/onc.2010.236","article-title":"The role of signaling pathways in the development and treatment of hepatocellular carcinoma","volume":"29","author":"Whittaker","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.colsurfb.2026.115981_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2019.05.004","article-title":"Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma","volume":"77","author":"Rimassa","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.colsurfb.2026.115981_bib15","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/diseases3040360","article-title":"Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future","volume":"3","author":"Ikeda","year":"2015","journal-title":"Diseases"},{"key":"10.1016\/j.colsurfb.2026.115981_bib16","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.3389\/fonc.2021.752725","article-title":"Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials","volume":"11","author":"Mou","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib17","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3748\/wjg.v29.i10.1551","article-title":"Systemic treatment for unresectable hepatocellular carcinoma","volume":"29","author":"Leowattana","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrg2985","article-title":"Ex vivo gene transfer and correction for cell-based therapies","volume":"12","author":"Naldini","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.colsurfb.2026.115981_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature19764","article-title":"In vitro and ex vivo strategies for intracellular delivery","volume":"538","author":"Stewart","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.colsurfb.2026.115981_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091265","article-title":"Current Status of Gene Therapy in Hepatocellular Carcinoma","volume":"11","author":"Reghupaty","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.colsurfb.2026.115981_bib21","first-page":"69","article-title":"Nanomedicine-boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma","volume":"9","author":"Lu","year":"2022","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib22","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.2147\/IJN.S115727","article-title":"Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma","volume":"11","author":"Li","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2026.115981_bib23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.4254\/wjh.v9.i21.907","article-title":"Chemotherapy for hepatocellular carcinoma: The present and the future","volume":"9","author":"Le Grazie","year":"2017","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101946","article-title":"Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma","volume":"82","author":"Vogel","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.colsurfb.2026.115981_bib25","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3762\/bjnano.9.98","article-title":"Review on nanoparticles and nanostructured materials: History, sources, toxicity and regulations","volume":"9","author":"Jeevanandam","year":"2018","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ph18030290","article-title":"Optimized Hesperidin-Loaded Lipid Nanoparticles with Tea Tree Oil for Enhanced Wound Healing: Formulation, Characterization, and Evaluation","volume":"18","author":"Arneth","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.colsurfb.2026.115981_bib27","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.2174\/1389450119666180326122831","article-title":"Nanoparticles in Cancer Treatment: Opportunities and Obstacles","volume":"19","author":"Awasthi","year":"2018","journal-title":"Curr. Drug. Targets"},{"key":"10.1016\/j.colsurfb.2026.115981_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.foodhyd.2014.05.010","article-title":"A review: Using nanoparticles to enhance absorption and bioavailability of phenolic phytochemicals","volume":"43","author":"Li","year":"2015","journal-title":"Food Hydrocoll."},{"key":"10.1016\/j.colsurfb.2026.115981_bib29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12951-022-01309-9","article-title":"Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances","volume":"20","author":"Mahmoud","year":"2022","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.colsurfb.2026.115981_bib30","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Invest. New. Drugs"},{"key":"10.1016\/j.colsurfb.2026.115981_bib31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/pharmaceutics14010041","article-title":"Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment","volume":"14","author":"Hatziantoniou","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2026.115981_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102508","article-title":"Current advances in nanoparticle-based approaches for the hepatocellular carcinoma treatment","volume":"49","author":"Paranthaman","year":"2025","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib33","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3389\/fmolb.2020.587012","article-title":"Nanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization","volume":"7","author":"Sanit\u00e0","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126094","article-title":"A review on protein corona formation on nanoparticles and prediction of its composition using artificial intelligence tools","volume":"683","author":"Ahmadi","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.colsurfb.2026.115981_bib35","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.3390\/biomedicines9101496","article-title":"Impact of Protein Corona on the Biological Identity of Nanomedicine: Understanding the Fate of Nanomaterials in the Biological Milieu","volume":"9","author":"Akhter","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.colsurfb.2026.115981_bib36","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41578-023-00552-2","article-title":"The protein corona from nanomedicine to environmental science","volume":"8","author":"Mahmoudi","year":"2023","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.colsurfb.2026.115981_bib37","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1021\/la401192x","article-title":"Time Evolution of Nanoparticle\u2013Protein Corona in Human Plasma: Relevance for Targeted Drug Delivery","volume":"29","author":"Barr\u00e1n-Berd\u00f3n","year":"2013","journal-title":"Langmuir"},{"key":"10.1016\/j.colsurfb.2026.115981_bib38","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1021\/nn100262h","article-title":"Rapid Uptake of Gold Nanorods by Primary Human Blood Phagocytes and Immunomodulatory Effects of Surface Chemistry","volume":"4","author":"Bartneck","year":"2010","journal-title":"ACS Nano"},{"key":"10.1016\/j.colsurfb.2026.115981_bib39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2020.06.017","article-title":"Lipid-based nanoparticle technologies for liver targeting","volume":"154-155","author":"B\u00f6ttger","year":"2020","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2026.115981_bib40","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1113\/jphysiol.2003.042713","article-title":"Effect of charge on interstitial distribution of albumin in rat dermis in vitro","volume":"550","author":"Wiig","year":"2003","journal-title":"J. Physiol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib41","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1039\/D5NR04462F","article-title":"Factors governing tumor penetration of nanomedicines: intrinsic and extrinsic determinants","volume":"18","author":"Shin","year":"2026","journal-title":"Nanoscale"},{"key":"10.1016\/j.colsurfb.2026.115981_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114635","article-title":"Protein corona: Friend or foe? Co-opting serum proteins for nanoparticle delivery","volume":"192","author":"Kim","year":"2023","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2026.115981_bib43","doi-asserted-by":"crossref","first-page":"342","DOI":"10.15386\/mpr-1756","article-title":"A review of the current understanding of nanoparticles protein corona composition","volume":"93","author":"Breznica","year":"2020","journal-title":"Med. Pharm. Rep."},{"key":"10.1016\/j.colsurfb.2026.115981_bib44","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nmat2442","article-title":"Understanding biophysicochemical interactions at the nano\u2013bio interface","volume":"8","author":"Nel","year":"2009","journal-title":"Nat. Mater."},{"key":"10.1016\/j.colsurfb.2026.115981_bib45","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1038\/s41467-026-70453-9","article-title":"Surface hydrophobicity and rigidity determines protein corona on orally delivered nanoparticles treating colitis","volume":"17","author":"Wu","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.colsurfb.2026.115981_bib46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2026.115981_bib47","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2217\/nnm.11.19","article-title":"Nanoparticle PEGylation for Imaging and Therapy","volume":"6","author":"Jokerst","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.colsurfb.2026.115981_bib48","doi-asserted-by":"crossref","first-page":"14265","DOI":"10.1073\/pnas.0805135105","article-title":"Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts","volume":"105","author":"Lundqvist","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib49","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.colsurfb.2014.06.016","article-title":"Nanoparticle size matters in the formation of plasma protein coronas on Fe3O4 nanoparticles","volume":"121","author":"Hu","year":"2014","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2026.115981_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116627","article-title":"Engineering the protein corona: Strategies, effects, and future directions in nanoparticle therapeutics","volume":"175","author":"Zhao","year":"2024","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.colsurfb.2026.115981_bib51","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.1038\/s41467-024-52416-0","article-title":"Transvascular transport of nanocarriers for tumor delivery","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.colsurfb.2026.115981_bib52","doi-asserted-by":"crossref","first-page":"13048","DOI":"10.3390\/ijms241713048","article-title":"Improving Cancer Targeting: A Study on the Effect of Dual-Ligand Density on Targeting of Cells Having Differential Expression of Target Biomarkers","volume":"24","author":"Sultana","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib53","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1021\/acsnano.9b05689","article-title":"Quantitative Study of the Interaction of Multivalent Ligand-Modified Nanoparticles with Breast Cancer Cells with Tunable Receptor Density","volume":"14","author":"Wang","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.colsurfb.2026.115981_bib54","doi-asserted-by":"crossref","first-page":"6886","DOI":"10.1021\/acsnano.2c02084","article-title":"Quantification of Available Ligand Density on the Surface of Targeted Liposomal Nanomedicines at the Single-Particle Level","volume":"16","author":"Chen","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.colsurfb.2026.115981_bib55","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1039\/D4NR03706E","article-title":"Understanding the interplay between pH and charges for theranostic nanomaterials","volume":"17","author":"Ow","year":"2025","journal-title":"Nanoscale"},{"key":"10.1016\/j.colsurfb.2026.115981_bib56","doi-asserted-by":"crossref","first-page":"16647","DOI":"10.1021\/jp8051906","article-title":"Computational Investigation of Interaction between Nanoparticles and Membranes: Hydrophobic\/Hydrophilic Effect","volume":"112","author":"Li","year":"2008","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.colsurfb.2026.115981_bib57","first-page":"2191","article-title":"Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures","volume":"10","author":"Murugan","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2026.115981_bib58","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/acs.accounts.9b00177","article-title":"Carriers Break Barriers in Drug Delivery: Endocytosis and Endosomal Escape of Gene Delivery Vectors","volume":"52","author":"Degors","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib59","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.addr.2019.04.008","article-title":"Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine","volume":"143","author":"Donahue","year":"2019","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2026.115981_bib60","article-title":"The Role of PI3K\/AKT\/mTOR Signaling in Hepatocellular Carcinoma Metabolism","volume":"24","author":"Tian","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib61","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K Pathway in Human Disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.colsurfb.2026.115981_bib62","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1872-034X.2008.00449.x","article-title":"Involvement of PI3K\/PTEN\/AKT\/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9","volume":"39","author":"Chen","year":"2009","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib63","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1002\/jcp.29333","article-title":"Role of regulatory miRNAs of the PI3K\/AKT\/mTOR signaling in the pathogenesis of hepatocellular carcinoma","volume":"235","author":"Rahmani","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15082130","article-title":"Targeting EGFR\/PI3K\/AKT\/mTOR Signaling in Hepatocellular Carcinoma","volume":"15","author":"Bang","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2026.115981_bib65","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.colsurfb.2026.115981_bib66","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.colsurfb.2026.115981_bib67","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1432-1033.1983.tb07140.x","article-title":"Glycogen Synthase from Rabbit Skeletal Muscle; Effect of Insulin on the State of phosphorylation of the Seven Phosphoserine Residues in vivo","volume":"130","author":"Parker","year":"1983","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.colsurfb.2026.115981_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106553","article-title":"Biological impact and therapeutic perspective of targeting PI3K\/Akt signaling in hepatocellular carcinoma: Promises and Challenges","volume":"187","author":"Paskeh","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.932156","article-title":"A new core\u2013shell-type nanoparticle loaded with paclitaxel\/norcantharidin and modified with APRPG enhances anti-tumor effects in hepatocellular carcinoma","volume":"12","author":"Xie","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib70","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.actbio.2020.04.046","article-title":"Hybrid membrane camouflaged copper sulfide nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma","volume":"111","author":"Ji","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.colsurfb.2026.115981_bib71","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/17425247.2023.2216451","article-title":"Size-optimized simvastatin-loaded TPGS modified lipid nanocapsules for targeting epithelial-to-mesenchymal transition in hepatocellular carcinoma: Role of PTEN\/AKT signaling","volume":"20","author":"Mahmoud","year":"2023","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"10.1016\/j.colsurfb.2026.115981_bib72","doi-asserted-by":"crossref","first-page":"57362","DOI":"10.1021\/acsami.0c17660","article-title":"Co-delivery of Sorafenib and CRISPR\/Cas9 Based on Targeted Core\u2013Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy","volume":"12","author":"Zhang","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.colsurfb.2026.115981_bib73","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1007\/s10620-014-3058-x","article-title":"Molecular therapies in hepatocellular carcinoma: what can we target?","volume":"59","author":"Galuppo","year":"2014","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/cells8101172","article-title":"Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link","volume":"8","author":"Chen","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.colsurfb.2026.115981_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13123026","article-title":"MAPK\/ERK Signaling Pathway in Hepatocellular Carcinoma","volume":"13","author":"Moon","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.colsurfb.2026.115981_bib76","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.4254\/wjh.v7.i15.1964","article-title":"G. Wang, Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy","volume":"7","author":"Chen","year":"2015","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib77","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/eci.12441","article-title":"The Ras\/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications","volume":"45","author":"Delire","year":"2015","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.colsurfb.2026.115981_bib78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: Structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib79","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.3892\/ol.2016.5110","article-title":"The Ras\/Raf\/MEK\/ERK signaling pathway and its role in the occurrence and development of HCC (Review)","volume":"12","author":"Li","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.colsurfb.2026.115981_bib80","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.colsurfb.2026.115981_bib81","article-title":"Preparation and evaluation of folate-decorated human serum albumin nanoparticles for the targeted delivery of sorafenib to enhance antihepatocarcinoma efficacy","volume":"54","author":"Gao","year":"2019","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib82","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.actbio.2017.04.029","article-title":"pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities","volume":"58","author":"Zhang","year":"2017","journal-title":"Acta Biomater."},{"key":"10.1016\/j.colsurfb.2026.115981_bib83","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000343828","article-title":"Treatment of Hepatocellular Carcinoma: A Systematic Review","volume":"1","author":"Lin","year":"2012","journal-title":"Liver Cancer"},{"key":"10.1016\/j.colsurfb.2026.115981_bib84","article-title":"Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.colsurfb.2026.115981_bib85","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s11671-020-03340-x","article-title":"Targeted Gene Silencing BRAF Synergized Photothermal Effect Inhibits Hepatoma Cell Growth Using New GAL-GNR-siBRAF Nanosystem","volume":"15","author":"Liu","year":"2020","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.colsurfb.2026.115981_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.00512","article-title":"Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA","volume":"8","author":"Zheng","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib87","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1186\/s12951-024-02827-4","article-title":"ACYP2 functions as an innovative nano-therapeutic target to impede the progression of hepatocellular carcinoma by inhibiting the activity of TERT and the KCNN4\/ERK pathway","volume":"22","author":"Wu","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.colsurfb.2026.115981_bib88","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","article-title":"CXCL12 (SDF-1)\/CXCR4 Pathway in Cancer","volume":"16","author":"Teicher","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib89","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.3892\/ol.2017.6396","article-title":"Role of C-X-C chemokine ligand 12\/C-X-C chemokine receptor 4 in the progression of hepatocellular carcinoma (Review)","volume":"14","author":"Jeng","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.colsurfb.2026.115981_bib90","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1471-2407-9-176","article-title":"Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival","volume":"9","author":"Xiang","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.colsurfb.2026.115981_bib91","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/febs.14466","article-title":"A guide to chemokines and their receptors","volume":"285","author":"Hughes","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.colsurfb.2026.115981_bib92","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrm908","article-title":"Seven-transmembrane receptors","volume":"3","author":"Pierce","year":"2002","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib93","article-title":"Emerging Importance of Chemokine Receptor CXCR4 and Its Ligand in Liver Disease","volume":"9","author":"Wang","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib94","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.cyto.2017.12.022","article-title":"Multisystem multitasking by CXCL12 and its receptors CXCR4 and ACKR3","volume":"109","author":"Murphy","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.colsurfb.2026.115981_bib95","doi-asserted-by":"crossref","first-page":"G203","DOI":"10.1152\/ajpgi.00193.2016","article-title":"Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases","volume":"311","author":"Liepelt","year":"2016","journal-title":"Am. J. Physiol. -Gastrointest. Liver Physiol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib96","first-page":"340","article-title":"Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis","volume":"6","author":"Ghanem","year":"2014","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib97","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11010-014-2020-8","article-title":"The SDF-1\/CXCR4 axis induces epithelial\u2013mesenchymal transition in hepatocellular carcinoma","volume":"392","author":"Li","year":"2014","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.colsurfb.2026.115981_bib98","first-page":"147","article-title":"CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment","volume":"17","author":"Wang","year":"2022","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.colsurfb.2026.115981_bib99","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13046-019-1216-x","article-title":"Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib","volume":"38","author":"Zheng","year":"2019","journal-title":"J. Exp. & Clin. Cancer Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.semcancer.2010.12.010","article-title":"Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad","volume":"21","author":"Nejak-Bowen","year":"2011","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib101","first-page":"1","article-title":"Caught up in a Wnt storm: Wnt signaling in cancer","volume":"1653","author":"Giles","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.colsurfb.2026.115981_bib102","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00018-023-05099-7","article-title":"Wnt\/\u03b2-catenin-driven EMT regulation in human cancers","volume":"81","author":"Xue","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib103","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154515","article-title":"\u03b2-Catenin signaling in hepatocellular carcinoma","volume":"132","author":"Xu","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.colsurfb.2026.115981_bib104","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.4254\/wjh.v7.i26.2631","article-title":"G.T. Saba, Wnt-\/-\u03b2-catenin pathway signaling in human hepatocellular carcinoma","volume":"7","author":"Waisberg","year":"2015","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.colsurfb.2026.115981_bib106","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3748\/wjg.v22.i2.823","article-title":"R. Gedaly, Targeting Wnt\/\u03b2-catenin pathway in hepatocellular carcinoma treatment","volume":"22","author":"Vilchez","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib107","article-title":"Wnt\/\u03b2-Catenin signaling pathway in hepatocellular carcinoma: pathogenic role and therapeutic target","volume":"14","author":"Zhao","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib108","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s11671-020-03451-5","article-title":"hGC33-Modified and Sorafenib-Loaded Nanoparticles have a Synergistic Anti-Hepatoma Effect by Inhibiting Wnt Signaling Pathway","volume":"15","author":"Shen","year":"2020","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.colsurfb.2026.115981_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118458","article-title":"Niclosamide-loaded polymeric micelles ameliorate hepatocellular carcinoma in vivo through targeting Wnt and Notch pathways","volume":"261","author":"Zeyada","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/ph17050645","article-title":"HGFK1 Enhances the Anti-Tumor Effects of Angiogenesis Inhibitors via Inhibition of CD90+ CSCs in Hepatocellular Carcinoma","volume":"17","author":"Li","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.colsurfb.2026.115981_bib111","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3350\/cmh.2020.0178","article-title":"Hepatic Hippo signaling inhibits development of hepatocellular carcinoma","volume":"26","author":"Liu","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib112","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030581","article-title":"High Risk of Hepatocellular Carcinoma Development in Fibrotic Liver: Role of the Hippo-YAP\/TAZ Signaling Pathway","volume":"20","author":"Moon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib113","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010430","article-title":"The YAP\/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises","volume":"23","author":"Ortega","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib114","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/261365","article-title":"Expression and Clinical Significance of YAP, TAZ, and AREG in Hepatocellular Carcinoma","volume":"2014","author":"Han","year":"2014","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib115","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ceb.2019.07.006","article-title":"Role of the transcriptional coactivators YAP\/TAZ in liver cancer","volume":"61","author":"Zhang","year":"2019","journal-title":"Curr. Opin. Cell. Biol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib116","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3892\/ijo.2024.5676","article-title":"Targeting the Hippo\/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review)","volume":"65","author":"Li","year":"2024","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib117","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.celrep.2015.02.027","article-title":"YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression","volume":"10","author":"Fitamant","year":"2015","journal-title":"Cell. Rep."},{"key":"10.1016\/j.colsurfb.2026.115981_bib118","article-title":"Heat-induced manganese-doped magnetic nanocarriers combined with Yap-siRNA for MRI\/NIR-guided mild photothermal and gene therapy of hepatocellular carcinoma","volume":"426","author":"Zhang","year":"2021","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.colsurfb.2026.115981_bib119","doi-asserted-by":"crossref","DOI":"10.1002\/smsc.202570013","article-title":"Therapeutic Glypican-3 CRISPR Genome-Editing Using UltraLarge Porous Silica Nano-Depot for the Treatment of Hepatocellular Carcinoma","volume":"5","author":"Lee","year":"2025","journal-title":"Small Sci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib120","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1600-065X.2012.01099.x","article-title":"NF-\u03baB and the link between inflammation and cancer","volume":"246","author":"DiDonato","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.colsurfb.2026.115981_bib121","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.colsurfb.2026.115981_bib122","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/cr.2010.183","article-title":"NF-\u03baB and STAT3 \u2013 key players in liver inflammation and cancer","volume":"21","author":"He","year":"2011","journal-title":"Cell. Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib123","doi-asserted-by":"crossref","DOI":"10.3390\/cells5020016","article-title":"The NF-\u03baB Pathway and Cancer Stem Cells","volume":"5","author":"Rinkenbaugh","year":"2016","journal-title":"Cells"},{"key":"10.1016\/j.colsurfb.2026.115981_bib124","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrgastro.2010.213","article-title":"NF-\u03baB in the liver--linking injury, fibrosis and hepatocellular carcinoma","volume":"8","author":"Luedde","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib125","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2147\/OTT.S161109","article-title":"Role of the NF\u03baB-signaling pathway in cancer","volume":"11","author":"Xia","year":"2018","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.colsurfb.2026.115981_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2023.115767","article-title":"Multifaceted role of NF-\u03baB in hepatocellular carcinoma therapy: Molecular landscape, therapeutic compounds and nanomaterial approaches","volume":"228","author":"Gupta","year":"2023","journal-title":"Environ. Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib127","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.nano.2018.09.002","article-title":"Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms","volume":"15","author":"Zhang","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.colsurfb.2026.115981_bib128","article-title":"Injectable Hydrogel-Encapsulating Pickering Emulsion for Overcoming Lenvatinib-Resistant Hepatocellular Carcinoma via Cuproptosis Induction and Stemness Inhibition","volume":"16","author":"Li","year":"2024","journal-title":"Polym. (Basel)"},{"key":"10.1016\/j.colsurfb.2026.115981_bib129","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1039\/D1MA00639H","article-title":"Selenium nanoparticles: a review on synthesis and biomedical applications","volume":"3","author":"Bisht","year":"2022","journal-title":"Mater. Adv."},{"key":"10.1016\/j.colsurfb.2026.115981_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120675","article-title":"Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-\u03baB pathways and LncRNA-AF085935\/GPC3 axis","volume":"303","author":"AL-Noshokaty","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib131","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.toxrep.2018.06.002","article-title":"Crosstalk between GSK-3, c-Fos, NF\u03baB and TNF-\u03b1 signaling pathways play an ambitious role in Chitosan Nanoparticles Cancer Therapy","volume":"5","author":"Kadry","year":"2018","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.colsurfb.2026.115981_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2020.124688","article-title":"Efficient CRISPR\/Cas9 gene-chemo synergistic cancer therapy via a stimuli-responsive chitosan-based nanocomplex elicits anti-tumorigenic pathway effect","volume":"393","author":"Zhang","year":"2020","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.colsurfb.2026.115981_bib133","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20130676","article-title":"Defining normoxia, physoxia and hypoxia in tumours\u2014implications for treatment response","volume":"87","author":"McKeown","year":"2014","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib134","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/409272","article-title":"The role of hypoxia inducible factor-1 in hepatocellular carcinoma","volume":"2014","author":"Luo","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.colsurfb.2026.115981_bib135","first-page":"3","article-title":"Hypoxia-inducible factors in hepatocellular carcinoma (Review)","volume":"43","author":"Guo","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.colsurfb.2026.115981_bib136","doi-asserted-by":"crossref","first-page":"12171","DOI":"10.3748\/wjg.v21.i42.12171","article-title":"J. Wu, Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target","volume":"21","author":"Lin","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib137","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0959-437X(00)00193-3","article-title":"P.J. Ratcliffe, Activation of the HIF pathway in cancer","volume":"11","author":"Maxwell","year":"2001","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.colsurfb.2026.115981_bib138","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/cdd.2008.12","article-title":"Biology of HIF-1\u03b1","volume":"15","author":"Weidemann","year":"2008","journal-title":"Cell. Death Differ."},{"key":"10.1016\/j.colsurfb.2026.115981_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112029","article-title":"Albendazole-loaded cubosomes interrupt the ERK1\/2-HIF-1\u03b1-p300\/CREB axis in mice intoxicated with diethylnitrosamine: A new paradigm in drug repurposing for the inhibition of hepatocellular carcinoma progression","volume":"142","author":"Saber","year":"2021","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.colsurfb.2026.115981_bib140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejpb.2015.03.003","article-title":"Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice","volume":"93","author":"Zhao","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2026.115981_bib141","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrc3365","article-title":"Mitochondria and cancer","volume":"12","author":"Wallace","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.colsurfb.2026.115981_bib142","article-title":"Mitochondrial Metabolic Signatures in Hepatocellular Carcinoma","volume":"10","author":"Lee","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.colsurfb.2026.115981_bib143","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.713721","article-title":"Mitochondrial Quality Control in Hepatocellular Carcinoma","volume":"11","author":"Bian","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib144","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.cdd.4401231","article-title":"Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis","volume":"10","author":"Gottlieb","year":"2003","journal-title":"Cell. Death Differ."},{"key":"10.1016\/j.colsurfb.2026.115981_bib145","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008706","article-title":"Mitochondrial regulation of cell death","volume":"5","author":"Tait","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib146","article-title":"Impact of Complex Apoptotic Signaling Pathways on Cancer Cell Sensitivity to Therapy","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.colsurfb.2026.115981_bib147","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/carcin\/bgy148","article-title":"Mitochondria in cancer: in the aspects of tumorigenesis and targeted therapy","volume":"39","author":"Badrinath","year":"2018","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.colsurfb.2026.115981_bib148","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nchembio.1712","article-title":"Targeting mitochondria metabolism for cancer therapy","volume":"11","author":"Weinberg","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib149","article-title":"Engineering of marizomib loaded polymeric nanoparticles: In vivo safety profile and In vitro proliferation in hepatocellular carcinoma","volume":"66","author":"Sui","year":"2021","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib150","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1007\/s11033-020-05455-x","article-title":"Cisplatin and farnesol co-encapsulated PLGA nano-particles demonstrate enhanced anti-cancer potential against hepatocellular carcinoma cells in vitro","volume":"47","author":"Mondal","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.colsurfb.2026.115981_bib151","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1021\/acs.jafc.0c03698","article-title":"Construction of Ginsenoside Nanoparticles with pH\/Reduction Dual Response for Enhancement of Their Cytotoxicity Toward HepG2 Cells","volume":"68","author":"Xu","year":"2020","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.colsurfb.2026.115981_bib152","doi-asserted-by":"crossref","DOI":"10.1093\/rb\/rbab046","article-title":"Integrin \u03b1v\u03b23-targeted polydopamine-coated gold nanostars for photothermal ablation therapy of hepatocellular carcinoma","volume":"8","author":"Li","year":"2021","journal-title":"Regen. Biomater."},{"key":"10.1016\/j.colsurfb.2026.115981_bib153","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1080\/21691401.2016.1269117","article-title":"Liposome-mediated RNA interference delivery against Erk1 and Erk2 does not equally promote chemosensitivity in human hepatocellular carcinoma cell line HepG2","volume":"45","author":"Mehdizadeh","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib154","article-title":"Asialoglycoprotein receptor-magnetic dual targeting nanoparticles for delivery of RASSF1A to hepatocellular carcinoma","volume":"6","author":"Xue","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.colsurfb.2026.115981_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105800","article-title":"Brefeldin A delivery nanomicelles in hepatocellular carcinoma therapy: Characterization, cytotoxic evaluation in vitro, and antitumor efficiency in vivo","volume":"172","author":"Zhang","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib156","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1565","article-title":"Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes 53-deficient cancers to mTOR inhibition","volume":"11","author":"Kong","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.colsurfb.2026.115981_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112813","article-title":"Preclinical evaluation of dalbergin loaded PLGA-galactose-modified nanoparticles against hepatocellular carcinoma via inhibition of the AKT\/NF-\u03baB signaling pathway","volume":"140","author":"Gautam","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib158","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1039\/D4NA00547C","article-title":"In vitro \u03b2-catenin attenuation by a mefloquine-loaded core-shell nano emulsion strategy to suppress liver cancer cells","volume":"7","author":"Mohapatra","year":"2025","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.colsurfb.2026.115981_bib159","doi-asserted-by":"crossref","first-page":"8309","DOI":"10.2147\/IJN.S184379","article-title":"Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration","volume":"13","author":"Huang","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2026.115981_bib160","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/1535-7163.MCT-11-0341","article-title":"A Polymeric Nanoparticle Encapsulated Small-Molecule Inhibitor of Hedgehog Signaling (NanoHHI) Bypasses Secondary Mutational Resistance to Smoothened Antagonists","volume":"11","author":"Chenna","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.colsurfb.2026.115981_bib161","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-11-0950","article-title":"Polymeric Nanoparticle-Encapsulated Hedgehog Pathway Inhibitor HPI-1 (NanoHHI) Inhibits Systemic Metastases in an Orthotopic Model of Human Hepatocellular Carcinoma","volume":"18","author":"Xu","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122865","article-title":"Targeted downregulation of MYC mediated by a highly efficient lactobionic acid-based glycoplex to enhance chemosensitivity in human hepatocellular carcinoma cells","volume":"637","author":"Santo","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2026.115981_bib163","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ejps.2017.10.036","article-title":"Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy","volume":"111","author":"Zheng","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib164","doi-asserted-by":"crossref","DOI":"10.1177\/03946320241263352","article-title":"Gemcitabine and synthesized silver nanoparticles impact on chemically induced hepatocellular carcinoma in male rats","volume":"38","author":"Mohamed","year":"2024","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib165","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.apsb.2021.02.001","article-title":"Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy","volume":"11","author":"Yu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.colsurfb.2026.115981_bib166","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.actbio.2019.09.034","article-title":"Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence","volume":"100","author":"Zhang","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.colsurfb.2026.115981_bib167","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40360-022-00589-z","article-title":"A novel nitidine chloride nanoparticle overcomes the stemness of CD133+EPCAM+ Huh7 hepatocellular carcinoma cells for liver cancer therapy","volume":"23","author":"Li","year":"2022","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2019.111496","article-title":"Golgi membrane protein GP73 modified-liposome mediates the antitumor effect of survivin promoter-driven HSVtk in hepatocellular carcinoma","volume":"383","author":"Liu","year":"2019","journal-title":"Exp. Cell. Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib169","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s41417-019-0145-3","article-title":"ApoE-modified liposomes mediate the antitumour effect of survivin promoter-driven HSVtk in hepatocellular carcinoma","volume":"27","author":"Mu","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.colsurfb.2026.115981_bib170","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202204342","article-title":"ALPPL2-Binding Peptide Facilitates Targeted mRNA Delivery for Efficient Hepatocellular Carcinoma Gene Therapy","volume":"32","author":"Lei","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.colsurfb.2026.115981_bib171","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092622","article-title":"Epigenetic Associations between lncRNA\/circRNA and miRNA in Hepatocellular Carcinoma","volume":"12","author":"Han","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.colsurfb.2026.115981_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115561","article-title":"Combating drug resistance in hepatocellular carcinoma: No awareness today, no action tomorrow","volume":"167","author":"Jing","year":"2023","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.colsurfb.2026.115981_bib173","doi-asserted-by":"crossref","DOI":"10.3390\/biom12050645","article-title":"Hepatocellular Carcinoma: The Role of MicroRNAs","volume":"12","author":"Khare","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.colsurfb.2026.115981_bib174","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41556-019-0311-8","article-title":"Cellular functions of long noncoding RNAs","volume":"21","author":"Yao","year":"2019","journal-title":"Nat. Cell. Biol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrgastro.2017.169","article-title":"Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications","volume":"15","author":"Wong","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111367","article-title":"Doxifluridine-based pharmacosomes delivering miR-122 as tumor microenvironments-activated nanoplatforms for synergistic treatment of hepatocellular carcinoma","volume":"197","author":"Xue","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2026.115981_bib177","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12645-021-00105-8","article-title":"A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation","volume":"12","author":"Hu","year":"2021","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib178","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801318","article-title":"Biodegradable Polymers as a Noncoding miRNA Nanocarrier for Multiple Targeting Therapy of Human Hepatocellular Carcinoma","volume":"8","author":"Yang","year":"2019","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.colsurfb.2026.115981_bib179","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s13046-024-03167-9","article-title":"Co-delivery of camptothecin and MiR-145 by lipid nanoparticles for MRI-visible targeted therapy of hepatocellular carcinoma","volume":"43","author":"Rong","year":"2024","journal-title":"J. Exp. & Clin. Cancer Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib180","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.omtn.2017.03.010","article-title":"MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma","volume":"7","author":"Fan","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.colsurfb.2026.115981_bib181","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/macromol4020009","article-title":"Mimic miRNA and Anti-miRNA Activated Scaffolds as a Therapeutic Strategy to Promote Bone, Cartilage, and Skin Regeneration","volume":"4","author":"Guelfi","year":"2024","journal-title":"Macromol"},{"key":"10.1016\/j.colsurfb.2026.115981_bib182","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.7150\/ijms.37427","article-title":"Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells","volume":"16","author":"Cai","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib183","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.actbio.2018.05.049","article-title":"A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy","volume":"75","author":"Li","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.colsurfb.2026.115981_bib184","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1039\/D0BM00794C","article-title":"Tumor-triggered personalized microRNA cocktail therapy for hepatocellular carcinoma","volume":"8","author":"Shao","year":"2020","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib185","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12943-022-01575-z","article-title":"M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma","volume":"21","author":"Du","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.colsurfb.2026.115981_bib186","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/IJN.S399318","article-title":"Nanoparticles Mediated circROBO1 Silencing to Inhibit Hepatocellular Carcinoma Progression by Modulating miR-130a-5p\/CCNT2 Axis","volume":"18","author":"Meng","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2026.115981_bib187","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s13346-022-01237-z","article-title":"Magnetically responsive nanoplatform targeting circRNA circ_0058051 inhibits hepatocellular carcinoma progression","volume":"13","author":"You","year":"2023","journal-title":"Drug. Deliv. Transl. Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e15288","article-title":"Nanoconjugated long non-coding RNA MEG3 as a new therapeutic approach for Hepatocellular carcinoma","volume":"9","author":"Elzallat","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.colsurfb.2026.115981_bib189","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13045-019-0839-x","article-title":"M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma","volume":"13","author":"Zuo","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib190","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2018.03158","article-title":"Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases","volume":"9","author":"Naran","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib191","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.109821","article-title":"Cancer immunotherapy: Pros, cons and beyond","volume":"124","author":"Tan","year":"2020","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.colsurfb.2026.115981_bib192","article-title":"Immunotherapy of hepatocellular carcinoma: recent progress and new strategy","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib193","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12134301","article-title":"Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment","volume":"12","author":"Alturki","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.colsurfb.2026.115981_bib194","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3748\/wjg.v29.i6.1054","article-title":"Immunotherapy for hepatocellular carcinoma: Current status and future perspectives","volume":"29","author":"Mandlik","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2023.141426","article-title":"Gold Nanorod\u2013mesoporous silica core shell nanocomposites for NIR-II photothermal ablation and dual PD-L1\/VEGF blockade therapy in hepatocellular carcinoma","volume":"459","author":"Dai","year":"2023","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.colsurfb.2026.115981_bib196","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12951-023-01967-3","article-title":"Isorhamnetin and anti-PD-L1 antibody dual-functional mesoporous silica nanoparticles improve tumor immune microenvironment and inhibit YY1-mediated tumor progression","volume":"21","author":"Liu","year":"2023","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.colsurfb.2026.115981_bib197","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12951-024-02399-3","article-title":"Self-delivery photothermal-boosted-nanobike multi-overcoming immune escape by photothermal\/chemical\/immune synergistic therapy against HCC","volume":"22","author":"Yang","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.colsurfb.2026.115981_bib198","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2024.06.030","article-title":"In-situ-formed immunotherapeutic and hemostatic dual drug-loaded nanohydrogel for preventing postoperative recurrence of hepatocellular carcinoma","volume":"372","author":"Ke","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2026.115981_bib199","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12645-020-00072-6","article-title":"Nanomedicine-mediated induction of immunogenic cell death and prevention of PD-L1 overexpression for enhanced hepatocellular carcinoma therapy","volume":"11","author":"Zhu","year":"2020","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib200","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.apsb.2024.04.033","article-title":"Triterpenoids-templated self-assembly nanosystem for biomimetic delivery of CRISPR\/Cas9 based on the synergy of TLR-2 and ICB to enhance HCC immunotherapy","volume":"14","author":"Zhang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.colsurfb.2026.115981_bib201","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12885-024-12006-1","article-title":"Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets","volume":"24","author":"Da","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.colsurfb.2026.115981_bib202","article-title":"Enhanced Targeting and Immune Activation of Tumor Microenvironment by Nanomodified Anti-PD1 in Liver Cancer","volume":"4","author":"Ou","year":"2021","journal-title":"Adv. Ther. (Weinh. )."},{"key":"10.1016\/j.colsurfb.2026.115981_bib203","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41419-024-06776-6","article-title":"A novel doxorubicin\/CTLA-4 blocker co-loaded drug delivery system improves efficacy and safety in antitumor therapy","volume":"15","author":"Yang","year":"2024","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.colsurfb.2026.115981_bib204","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4254\/wjh.v15.i4.515","article-title":"Ablative strategies for recurrent hepatocellular carcinoma","volume":"15","author":"Wang","year":"2023","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib205","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jconrel.2024.10.069","article-title":"Anti-CTLA-4 antibody self-presented dendritic cell nanovesicles boost the immunotherapy of hepatocellular carcinoma after microwave ablation","volume":"376","author":"Li","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2026.115981_bib206","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41420-023-01356-7","article-title":"Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy","volume":"9","author":"Zheng","year":"2023","journal-title":"Cell. Death Discov."},{"key":"10.1016\/j.colsurfb.2026.115981_bib207","doi-asserted-by":"crossref","first-page":"22109","DOI":"10.1002\/cam4.6717","article-title":"The role of tumor-associated macrophages in hepatocellular carcinoma progression: A narrative review","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.colsurfb.2026.115981_bib208","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41419-024-06888-z","article-title":"Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma","volume":"15","author":"Li","year":"2024","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.colsurfb.2026.115981_bib209","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00262-024-03748-9","article-title":"The significance of lipid metabolism reprogramming of tumor-associated macrophages in hepatocellular carcinoma","volume":"73","author":"Xie","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.colsurfb.2026.115981_bib210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114990","article-title":"Targeting tumor associated macrophages in hepatocellular carcinoma","volume":"199","author":"Xu","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib211","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg2697","article-title":"d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma","volume":"9","author":"Han","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.colsurfb.2026.115981_bib212","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41467-022-28279-8","article-title":"Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy","volume":"13","author":"Xiao","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.colsurfb.2026.115981_bib213","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1186\/s12967-024-05917-x","article-title":"Napabucasin-loaded PLGA nanoparticles trigger anti-HCC immune responses by metabolic reprogramming of tumor-associated macrophages","volume":"22","author":"Song","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.colsurfb.2026.115981_bib214","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.omto.2021.08.008","article-title":"Multiple targeted self-emulsifying compound RGO reveals obvious anti-tumor potential in hepatocellular carcinoma","volume":"22","author":"He","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.colsurfb.2026.115981_bib215","article-title":"Supramolecular Polymer-Nanomedicine Hydrogel Loaded with Tumor Associated Macrophage-Reprogramming polyTLR7\/8a Nanoregulator for Enhanced Anti-Angiogenesis Therapy of Orthotopic Hepatocellular Carcinoma","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib216","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41388-019-1108-8","article-title":"The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma","volume":"39","author":"Thomsen","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.colsurfb.2026.115981_bib217","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/imcb.12555","article-title":"Control of innate immunity by the cGAS-STING pathway","volume":"100","author":"Mosallanejad","year":"2022","journal-title":"Immunol. Cell. Biol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib218","article-title":"cGAS-STING Signaling Pathway and Liver Disease: From Basic Research to Clinical Practice","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.colsurfb.2026.115981_bib219","article-title":"The role of cGAS-STING signalling in liver diseases","volume":"3","author":"Chen","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.colsurfb.2026.115981_bib220","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.102090","article-title":"Harnessing a triphenylphosphine-based AIE nano-platform for triggering incomplete mitophagy to continuously augment anti-tumor immune response in hepatocellular carcinoma","volume":"54","author":"Song","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.colsurfb.2026.115981_bib221","article-title":"Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer","volume":"6","author":"Huang","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.colsurfb.2026.115981_bib222","doi-asserted-by":"crossref","DOI":"10.3390\/nano13121828","article-title":"An Overview of the Use of Nanoparticles in Vaccine Development","volume":"13","author":"Lozano","year":"2023","journal-title":"Nanomaterials"},{"key":"10.1016\/j.colsurfb.2026.115981_bib223","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12951-024-02354-2","article-title":"Smart responsive Fe\/Mn nanovaccine triggers liver cancer immunotherapy via pyroptosis and pyroptosis-boosted cGAS-STING activation","volume":"22","author":"Du","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.colsurfb.2026.115981_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/j.inoche.2024.113765","article-title":"Unveiling the therapeutic potential of ultrasound-responsive micro\/nanobubbles in cancer management","volume":"172","author":"Mahmoodi","year":"2025","journal-title":"Inorg. Chem. Commun."},{"key":"10.1016\/j.colsurfb.2026.115981_bib225","first-page":"471","article-title":"Drug delivery system based on nanobubbles","volume":"1","author":"Jin","year":"2022","journal-title":"Interdiscip. Mater."},{"key":"10.1016\/j.colsurfb.2026.115981_bib226","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030480","article-title":"Mechanistic Insights and Therapeutic Delivery through Micro\/Nanobubble-Assisted Ultrasound","volume":"14","author":"Lu","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2026.115981_bib227","doi-asserted-by":"crossref","DOI":"10.3390\/biomimetics9100645","article-title":"Clinical Applications of Micro\/Nanobubble Technology in Neurological Diseases","volume":"9","author":"Patel","year":"2024","journal-title":"Biomimetics"},{"key":"10.1016\/j.colsurfb.2026.115981_bib228","article-title":"Ultrasound-Mediated Drug Delivery: Sonoporation Mechanisms, Biophysics, and Critical Factors","volume":"2024","author":"Tu","year":"2022","journal-title":"BME Front."},{"key":"10.1016\/j.colsurfb.2026.115981_bib229","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.2147\/IJN.S376172","article-title":"Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma","volume":"17","author":"Chen","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2026.115981_bib230","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.3892\/or.2015.4270","article-title":"Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells","volume":"34","author":"Liu","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.colsurfb.2026.115981_bib231","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.2147\/IJN.S426297","article-title":"Sono-Immunotherapy Mediated Controllable Composite Nano Fluorescent Probes Reprogram the Immune Microenvironment of Hepatocellular Carcinoma","volume":"18","author":"Chen","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2026.115981_bib232","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202000269","article-title":"Advances in Exosomes-Based Drug Delivery Systems","volume":"21","author":"Gutierrez-Millan","year":"2021","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib233","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejpb.2020.07.026","article-title":"Exosomes as drug delivery systems: A brief overview and progress update","volume":"154","author":"Patil","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2026.115981_bib234","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12951-018-0403-9","article-title":"Recent advancements in the use of exosomes as drug delivery systems","volume":"16","author":"Bunggulawa","year":"2018","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.colsurfb.2026.115981_bib235","doi-asserted-by":"crossref","DOI":"10.1016\/j.vesic.2023.100032","article-title":"Exosome as drug delivery system: Current advancements","volume":"3","author":"Sharma","year":"2024","journal-title":"Extracell. Vesicle"},{"key":"10.1016\/j.colsurfb.2026.115981_bib236","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1080\/10717544.2022.2118898","article-title":"Delivery of human natural killer cell-derived exosomes for liver cancer therapy: an in vivo study in subcutaneous and orthotopic animal models","volume":"29","author":"Kim","year":"2022","journal-title":"Drug. Deliv."},{"key":"10.1016\/j.colsurfb.2026.115981_bib237","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13046-019-1512-5","article-title":"MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway","volume":"39","author":"Lou","year":"2020","journal-title":"J. Exp. & Clin. Cancer Res."},{"key":"10.1016\/j.colsurfb.2026.115981_bib238","article-title":"Ligand-displaying-exosomes using RNA nanotechnology for targeted delivery of multi-specific drugs for liver cancer regression","volume":"50","author":"Ellipilli","year":"2023","journal-title":"Nanomedicine"},{"key":"10.1016\/j.colsurfb.2026.115981_bib239","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2015.03.002","article-title":"Engineering mesenchymal stem cells for regenerative medicine and drug delivery","volume":"84","author":"Park","year":"2015","journal-title":"Methods"},{"key":"10.1016\/j.colsurfb.2026.115981_bib240","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/sctm.18-0024","article-title":"Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise","volume":"7","author":"Krueger","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.colsurfb.2026.115981_bib241","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28052130","article-title":"Enhanced Drug Delivery System Using Mesenchymal Stem Cells and Membrane-Coated Nanoparticles","volume":"28","author":"Joshi","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.colsurfb.2026.115981_bib242","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2018.12.019","article-title":"Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic","volume":"294","author":"Wu","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2026.115981_bib243","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.addr.2010.08.010","article-title":"Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery","volume":"62","author":"Porada","year":"2010","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2026.115981_bib244","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120477","article-title":"Current advances and challenges of mesenchymal stem cells-based drug delivery system and their improvements","volume":"600","author":"Su","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2026.115981_bib245","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1080\/15384047.2016.1177675","article-title":"Overexpression of hepatocyte nuclear factor 4\u03b1 in human mesenchymal stem cells suppresses hepatocellular carcinoma development through Wnt\/\u03b2-catenin signaling pathway downregulation","volume":"17","author":"Wu","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.colsurfb.2026.115981_bib246","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.lfs.2015.10.031","article-title":"Interferon-\u03b12b gene-modified human bone marrow mesenchymal stem cells inhibit hepatocellular carcinoma by reducing the Notch1 levels","volume":"143","author":"Su","year":"2015","journal-title":"Life Sci."},{"key":"10.1016\/j.colsurfb.2026.115981_bib247","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3748\/wjg.v25.i5.567","article-title":"Effect of adipose-derived mesenchymal stem cells on hepatocellular carcinoma: In vitro inhibition of carcinogenesis","volume":"25","author":"Serhal","year":"2019","journal-title":"World J. Gastroenterol."}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776526005692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776526005692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:33:12Z","timestamp":1788528792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776526005692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":247,"alternative-id":["S0927776526005692"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2026.115981","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reprogramming hepatocellular carcinoma: Nanomedicine at the crossroads of molecular targets and smart delivery","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2026.115981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115981"}}